ClouDr Partners with Shaanxi Pharmaceutical Firms for Integrated Healthcare Solutions
Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), better known as “ClouDr,” has announced...
Syneos Health Partners with Fosun Pharma to Commercialize Serplulimab in US
US-based Syneos Health (Nasdaq: SYNH) has revealed a strategic partnership with Fosun Pharma USA Inc.,...
Sanofi’s iGlarLixi Approved in China for Type 2 Diabetes Management
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced that the National Medical Products Administration (NMPA)...
Roche’s Polivy Approved by China’s NMPA for Lymphoma Treatment
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced that the National Medical Products...
China Launches Eighth Round of National Volume-Based Procurement for 41 Drugs
The National Healthcare Security Administration has issued a notice to initiate the COVID-delayed eighth round...
Med Vision Secures A+ Round Financing to Accelerate Digital Therapy Commercialization
Hangzhou-based Med Vision Technology Co., Ltd. has successfully completed an A+ round financing, raising several...
MSD China to Take Legal Action Against Market Infringement of Molnupiravir
Merck Sharp & Dohme (MSD, NYSE: MRK)’s China unit has issued a WeChat notification vowing...
Med Vision Secures Series A+ Funding to Expand Digital Therapy Portfolio
Med Vision, a Hangzhou-based digital therapy specialist, has reportedly raised “tens of millions” of renminbi...
Kexing Pharmaceutical Initiates Phase I Trial for IFN-Alpha-1b Inhalation Solution
China-based Kexing Pharmaceutical (SHA: 688136) has announced the enrollment of the first subject and dosing...
Bioantibody Bio Raises RMB 100 Million in Series A Funding Round
Bioantibody Biotechnology Co., Ltd, a Nanjing-based in vitro diagnostics (IVD) and biologic company, has reportedly...
Meihua Partners with Getein Biotech to Manufacture COVID-19 Antigen Tests
China-based Meihua International Medical Technologies Co., Ltd (NASDAQ: MHUA) has announced a strategic partnership with...
CSPC’s Cleviprex Approved for Clinical Study by China’s NMPA
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical...
China’s Dental Implant VBP Tender Results in Significant Price Cuts
The results of the dental implant system-focused volume-based procurement (VBP) tender held in Sichuan have...
Takeda’s Mobocertinib Approved in China for EGFR Exon20ins NSCLC
Japan-based Takeda Pharmaceutical Co., Ltd’s (TYO: 4502) China unit has announced receiving marketing approval from...
MediTrust Health Secures Series C+ Funding with HSBC as Strategic Investor
MediTrust Health, the insurance, financing, and direct-to-patient pharmacy subsidiary of China-based Shanghai Pharmaceuticals Holding Co.,...
Kelun-Biotech’s SKB264 Approved for Phase II Study in EGFR-Mutant NSCLC
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd has announced receiving approval from the National Medical Products...
BeiGene Outlines Global R&D Strategy at J.P. Morgan Healthcare Summit
China-based biotech BeiGene (Nasdaq: BGNE, HKG: 6160) provided an update on its company strategy and...
Evopoint Biosciences Licenses SOS1 Inhibitor to METiS Therapeutics
China-based Evopoint Biosciences has announced a global licensing agreement with US firm METiS Therapeutics Inc.,...
Pfizer’s Nurtec ODT Launches in China via Hainan’s Bo’Ao Lecheng Zone
US-based Pfizer’s (NYSE: PFE) Nurtec ODT (rimegepant), the world’s first calcitonin gene-related peptide (CGRP) receptor...
HKEX 2022 Annual Report: IPO Activity Declines Amid Global Challenges
The Hong Kong Exchanges and Clearing Ltd (HKEX) has released its annual report for 2022,...